United Therapeutics (NASDAQ:UTHR) CEO Martine Rothblatt Sells 4,000 Shares

United Therapeutics Corporation (NASDAQ:UTHR) CEO Martine Rothblatt sold 4,000 shares of United Therapeutics stock in a transaction dated Wednesday, November 19th. The shares were sold at an average price of $474.58, for a total transaction of $1,898,320.00. Following the sale, the chief executive officer owned 130 shares of the company’s stock, valued at approximately $61,695.40. This represents a 96.85% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

United Therapeutics Stock Performance

Shares of UTHR traded down $1.82 during midday trading on Thursday, hitting $474.72. 398,028 shares of the stock were exchanged, compared to its average volume of 590,566. The firm has a market cap of $20.44 billion, a P/E ratio of 17.99, a P/E/G ratio of 4.96 and a beta of 0.77. United Therapeutics Corporation has a 52-week low of $266.98 and a 52-week high of $485.32. The stock has a fifty day simple moving average of $436.99 and a 200 day simple moving average of $353.41.

United Therapeutics (NASDAQ:UTHR) last issued its quarterly earnings results on Wednesday, October 29th. The biotechnology company reported $7.16 earnings per share (EPS) for the quarter, topping the consensus estimate of $6.89 by $0.27. United Therapeutics had a net margin of 40.65% and a return on equity of 18.83%. The business had revenue of $799.50 million for the quarter, compared to analysts’ expectations of $812.87 million. During the same quarter in the prior year, the company earned $6.39 earnings per share. The business’s quarterly revenue was up 6.8% on a year-over-year basis. As a group, equities research analysts forecast that United Therapeutics Corporation will post 24.48 EPS for the current fiscal year.

Institutional Trading of United Therapeutics

A number of institutional investors have recently bought and sold shares of UTHR. Chung Wu Investment Group LLC acquired a new stake in United Therapeutics during the second quarter worth approximately $29,000. WealthCollab LLC boosted its holdings in shares of United Therapeutics by 55.9% in the 2nd quarter. WealthCollab LLC now owns 106 shares of the biotechnology company’s stock valued at $30,000 after buying an additional 38 shares in the last quarter. Rakuten Securities Inc. grew its position in shares of United Therapeutics by 76.7% in the 2nd quarter. Rakuten Securities Inc. now owns 106 shares of the biotechnology company’s stock valued at $30,000 after buying an additional 46 shares during the last quarter. SVB Wealth LLC acquired a new stake in United Therapeutics during the 1st quarter worth $32,000. Finally, Wilmington Savings Fund Society FSB lifted its position in United Therapeutics by 125.6% in the third quarter. Wilmington Savings Fund Society FSB now owns 88 shares of the biotechnology company’s stock valued at $37,000 after acquiring an additional 49 shares during the last quarter. 94.08% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several equities analysts have commented on the stock. Weiss Ratings restated a “buy (b-)” rating on shares of United Therapeutics in a research note on Wednesday. Jefferies Financial Group reiterated a “buy” rating and issued a $575.00 target price on shares of United Therapeutics in a report on Wednesday. Wells Fargo & Company upped their price target on United Therapeutics from $414.00 to $423.00 and gave the stock an “equal weight” rating in a report on Thursday, October 30th. Royal Bank Of Canada increased their price target on United Therapeutics from $569.00 to $587.00 and gave the company an “outperform” rating in a research report on Thursday, October 30th. Finally, Morgan Stanley set a $447.00 price objective on United Therapeutics in a research report on Wednesday, October 29th. Eight equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $505.00.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.